Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Disitamab Vedotin + Tislelizumab in HER2+ Advanced CRC
NCT05493683Phase 2Unknown
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Aug 2022
- Primary completion
- Jul 2025
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
A Phase 2 trial of disitamab vedotin, tislelizumab in colorectal cancer (CRC), sponsored by Jiangsu Provincial People's Hospital. Status: unknown.
02
Drugs
disitamab vedotintislelizumab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT05493683.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05493683.